SpringWorks Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$1.33 | -$0.93 | -$1.17 |
| Q2 2024 | 3 | -$1.27 | -$0.88 | -$1.12 |
| Q3 2024 | 5 | -$0.94 | -$0.59 | -$0.75 |
| Q4 2024 | 3 | -$0.77 | -$0.54 | -$0.68 |
| Q1 2025 | 4 | -$0.58 | -$0.41 | -$0.51 |
| Q2 2025 | 4 | -$0.46 | -$0.32 | -$0.40 |
| Q3 2025 | 4 | -$0.27 | -$0.19 | -$0.24 |
| Q4 2025 | 4 | -$0.02 | -$0.01 | -$0.02 |
SpringWorks Therapeutics, Inc. Earnings Date And Information
SpringWorks Therapeutics, Inc. last posted its earnings results on Wednesday, August 7th, 2024. The company reported $-0.54 earnings per share for the quarter, topping analysts' consensus estimates of $-1.12 by $0.58. The company had revenue of 59.73 M for the quarter and had revenue of 5.45 M for the year. SpringWorks Therapeutics, Inc. has generated $-5 earnings per share over the last year ($-5.15 diluted earnings per share) and currently has a price-to-earnings ratio of -7.95. SpringWorks Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 31st, 2024 based on prior year's report dates.
SpringWorks Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/07/2024 | Q2 2024 | -$1.12 | -$0.54 | 0.58 | $34.42 M | $59.73 M |
| 05/02/2024 | Q1 2024 | -$1.17 | -$1.18 | -0.01 | $21.01 M | |
| 02/27/2024 | Q4 2023 | -$1.25 | -$1.28 | -0.03 | $5.45 M | |
| 11/02/2023 | Q3 2023 | -$1.31 | -$1.27 | 0.04 | $5.59 M | |
| 08/02/2023 | Q2 2023 | -$1.25 | -$1.25 | 0 | $5.83 M | |
| 05/03/2023 | Q1 2023 | -$1.25 | -$1.11 | 0.14 | $5.56 M | |
| 02/28/2023 | Q4 2022 | -$1.21 | -$1.12 | 0.09 | $5.80 M | |
| 11/03/2022 | Q3 2022 | -$1.31 | -$1.35 | -0.04 | $838,000 | |
| 08/04/2022 | Q2 2022 | -$1.26 | -$1.41 | -0.15 | $348,000 | |
| 05/05/2022 | Q1 2022 | -$1.07 | -$1.26 | -0.19 | $5,000 | |
| 02/24/2022 | Q4 2021 | -$0.87 | -$1.15 | -0.28 | $0 | |
| 11/04/2021 | Q3 2021 | -$0.77 | -$0.84 | -0.07 | $121,000 | |
| 08/04/2021 | Q2 2021 | -$0.70 | -$0.97 | -0.27 | $170,000 | |
| 05/05/2021 | Q1 2021 | -$0.62 | $230,000 | |||
| 02/25/2021 | Q4 2020 | -$0.10 | $0.30 | 0.4 | $35.00 M | |
| 11/12/2020 | Q3 2020 | -$0.49 | -$0.51 | -0.02 | $0 | |
| 08/12/2020 | Q2 2020 | -$0.31 | -$0.47 | -0.16 | $0 | |
| 05/12/2020 | Q1 2020 | -$0.40 | -$0.37 | 0.03 | $0 | |
| 03/12/2020 | Q4 2019 | -$0.36 | -$0.38 | -0.02 | $0 | |
| 11/12/2019 | Q3 2019 | -$0.47 | -$1.77 | -1.3 | $0 |
SpringWorks Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is SpringWorks Therapeutics, Inc.'s earnings date?
SpringWorks Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 31st, 2024 based off last year's report dates.
-
Did SpringWorks Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, SpringWorks Therapeutics, Inc. (:SWTX) reported $-0.54 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.12 by $0.58.
-
How can I listen to SpringWorks Therapeutics, Inc.'s earnings conference call?
The conference call for SpringWorks Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read SpringWorks Therapeutics, Inc.'s conference call transcript?
The conference call transcript for SpringWorks Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does SpringWorks Therapeutics, Inc. generate each year?
SpringWorks Therapeutics, Inc. (:SWTX) has a recorded annual revenue of $5.45 M.
-
How much profit does SpringWorks Therapeutics, Inc. generate each year?
SpringWorks Therapeutics, Inc. (:SWTX) has a recorded net income of $5.45 M. SpringWorks Therapeutics, Inc. has generated $-5.15 earnings per share over the last four quarters.
-
What is SpringWorks Therapeutics, Inc.'s price-to-earnings ratio?
SpringWorks Therapeutics, Inc. (:SWTX) has a price-to-earnings ratio of -7.95 and price/earnings-to-growth ratio is 40.85.
